Revenue remains highly volatile with a nominal $76.0K reported in 2026Q1, while negative gross margins of -13.8% underscore the inefficiency of the current isotope supply chain.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Jun'22 | Jun'21 | Jun'20 | Jun'19 | Jun'18 | Jun'17 | Jun'16 | Jun'15 | Jun'14 | Jun'13 | Jun'12 | Jun'11 | Jun'10 | Jun'09 | Jun'08 | Jun'07 | Jun'06 | Jun'05 | Sep'03 | Sep'02 | Sep'01 | Sep'00 | Sep'99 | Sep'98 | Sep'97 | Sep'96 |
|---|
| Sales/Revenue | 575K | 0 | 0 | 1.43M | 7.1M | 10.79M | 10.05M | 9.68M | 7.31M | 5.92M | 4.76M | 4.77M | 4.61M | 4.22M | 4.53M | 5.07M | 5.24M | 5.29M | 5.42M | 7.16M | 5.74M | 1.99M | 201.73K | 0 | 0 | 0 | 0 | 0 | 0 | 7.85M | 8.26M |
| Revenue Growth % | - | - | -100% | -79.81% | -34.19% | 7.38% | 3.85% | 32.35% | 23.48% | 24.41% | -0.17% | 3.53% | 9.18% | -6.76% | -10.76% | -3.2% | -0.89% | -2.43% | -24.32% | 24.76% | 187.72% | 888.6% | - | - | - | - | - | - | -100% | -4.96% | 5.64% |
| Cost of Goods Sold | 2.63M | 0 | 0 | 0 | 5.47M | 6.18M | 4.93M | 4.56M | 4.27M | 4.08M | 3.92M | 4.64M | 4.44M | 4.42M | 4.38M | 4.37M | 4.08M | 4.56M | 5.77M | 7.31M | 5.79M | 3.82M | 1.47M | 0 | 0 | 0 | 0 | 0 | 0 | 6.68M | 7.46M |
| COGS % of Revenue | - | - | - | - | 77% | 57.24% | 49.06% | 47.07% | 58.34% | 68.9% | 82.4% | 97.29% | 96.37% | 104.66% | 96.68% | 86.13% | 77.91% | 86.27% | 106.52% | 102.12% | 100.95% | 191.3% | 730.8% | - | - | - | - | - | - | 85.16% | 90.37% |
| Gross Profit | -2.06M | 0 | 0 | 1.43M | 1.63M | 4.62M | 5.12M | 5.12M | 3.05M | 1.84M | 838K | 129.15K | 167.39K | -196.47K | 150.18K | 703.2K | 1.16M | 725.8K | -353.33K | -151.43K | -54.6K | -1.82M | -1.27M | 0 | 0 | 0 | 0 | 0 | 0 | 1.16M | 795.61K |
| Gross Margin % | -358.09% | - | - | 100% | 23% | 42.76% | 50.94% | 52.93% | 41.66% | 31.1% | 17.6% | 2.71% | 3.63% | -4.66% | 3.32% | 13.87% | 22.09% | 13.73% | -6.52% | -2.12% | -0.95% | -91.3% | -630.8% | - | - | - | - | - | - | 14.84% | 9.63% |
| Gross Profit Growth % | - | - | -100% | -12.24% | -64.6% | -9.86% | -0.06% | 68.17% | 65.42% | 119.81% | 548.84% | -22.84% | 185.2% | -230.83% | -78.64% | -39.24% | 59.47% | 305.41% | -133.32% | -177.37% | 97% | -43.09% | - | - | - | - | - | - | -100% | 46.38% | -3.24% |
| Operating Expenses | 117.95M | 113.56M | 92.34M | 42.38M | 17.43M | 12.01M | 8.56M | 8.6M | 8.32M | 8.57M | 7.14M | 5.21M | 4.5M | 4.39M | 4.22M | 4.3M | 4.12M | 4.73M | 6.12M | 8.65M | 9.65M | 5.37M | 2.71M | 19.02K | 7.58K | 15.57K | 14.15K | 15.53K | 222.82K | 1.43M | 2.91M |
| OpEx % of Revenue | - | - | - | 2955.02% | 245.3% | 111.23% | 85.13% | 88.84% | 113.82% | 144.71% | 150.07% | 109.27% | 97.76% | 104.09% | 93.2% | 84.82% | 78.65% | 89.57% | 112.91% | 120.85% | 168.09% | 269.49% | 1343.71% | - | - | - | - | - | - | 18.16% | 35.18% |
| Selling, General & Admin | 29.38M | 30.23M | 26.61M | 21.06M | 14.21M | 9.43M | 7.13M | 7.55M | 6.85M | 6.83M | 6.23M | 5.14M | 3.89M | 3.72M | 3.59M | 3.57M | 3.66M | 4.39M | 5.16M | 7.29M | 8.3M | 4.92M | 2.57M | 19.02K | 7.58K | 7.58K | 0 | 15.53K | 221.88K | 1.11M | 2.59M |
| SG&A % of Revenue | - | - | - | 1468.9% | 200.08% | 87.31% | 70.93% | 77.96% | 93.67% | 115.23% | 130.81% | 107.76% | 84.42% | 88.24% | 79.34% | 70.41% | 69.77% | 83.12% | 95.22% | 101.88% | 144.65% | 246.9% | 1275.53% | - | - | - | - | - | - | 14.11% | 31.35% |
| Research & Development | 85.68M | 84.22M | 41.64M | 21.31M | 2.6M | 2.58M | 1.43M | 1.13M | 1.47M | 1.75M | 965K | 528.05K | 614.77K | 668.8K | 627.11K | 730.58K | 465.33K | 340.96K | 958.66K | 1.36M | 1.35M | 450.43K | 137.53K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | - | - | 1486.12% | 36.63% | 23.92% | 14.19% | 11.63% | 20.15% | 29.48% | 20.27% | 11.07% | 13.35% | 15.85% | 13.86% | 14.41% | 8.88% | 6.45% | 17.69% | 18.97% | 23.44% | 22.59% | 68.18% | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 182K | -884K | 24.09M | 0 | 0 | 0 | 0 | -73K | 2K | 0 | -48K | -456.28K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7.99K | 15.57K | 0 | 0 | 942 | 317.97K |
| Operating Income | -120.01M | -113.56M | 10.46M | -40.94M | -15.18M | -7.39M | -3.44M | -3.48M | -5.28M | -6.73M | -6.31M | -5.08M | -4.34M | -4.59M | -4.07M | -3.6M | -2.96M | -4.01M | -6.47M | -8.8M | -9.7M | -7.2M | -3.98M | -19.02K | -7.58K | -15.57K | -14.15K | -15.53K | -222.82K | -260.71K | -2.11M |
| Operating Margin % | -20871.83% | - | - | -2855.02% | -213.71% | -68.47% | -34.19% | -35.91% | -72.16% | -113.61% | -132.47% | -106.56% | -94.13% | -108.75% | -89.88% | -70.95% | -56.56% | -75.84% | -119.43% | -122.97% | -169.04% | -360.79% | -1974.51% | - | - | - | - | - | - | -3.32% | -25.55% |
| Operating Income Growth % | - | -1185.8% | 125.55% | -169.67% | -105.41% | -115.04% | 1.12% | 34.14% | 21.56% | -6.69% | -24.1% | -17.2% | 5.49% | -12.81% | -13.04% | -21.43% | 26.09% | 38.04% | 26.49% | 9.25% | -34.81% | -80.64% | -20839.96% | -150.82% | 51.29% | -10.04% | 8.89% | 93.03% | 14.53% | 87.64% | -154.81% |
| EBITDA | -116.37M | -110.31M | 10.46M | -39.96M | -14.84M | -7.14M | -3.43M | -3.33M | -5.3M | -6.65M | -6.24M | -4.61M | -3.76M | -3.9M | -3.33M | -2.75M | -2.07M | -3.01M | -5.26M | -7.74M | -8.98M | -6.54M | -3.84M | 65.83K | -48.59K | -67.07K | 236.53K | -67.03K | -221.88K | 57.26K | -1.79M |
| EBITDA Margin % | -20237.91% | - | - | -2786.61% | -208.87% | -66.17% | -34.1% | -34.39% | -72.49% | -112.26% | -131.04% | -96.68% | -81.62% | -92.5% | -73.55% | -54.25% | -39.6% | -56.98% | -97.15% | -108.15% | -156.58% | -327.93% | -1903.61% | - | - | - | - | - | - | 0.73% | -21.71% |
| EBITDA Growth % | -19.94% | -1154.72% | 126.17% | -169.31% | -107.73% | -108.37% | -2.97% | 37.21% | 20.26% | -6.57% | -35.3% | -22.64% | 3.66% | -17.27% | -20.98% | -32.61% | 31.13% | 42.78% | 32.01% | 13.83% | -37.38% | -70.3% | -5933.45% | 235.48% | 27.55% | -128.36% | 452.87% | 69.79% | -487.49% | 103.19% | -326.36% |
| D&A (Non-Cash Add-back) | 3.65M | 3.25M | 0 | 981K | 344K | 248K | 9K | 147K | -24K | 80K | 68K | 470.85K | 576.38K | 685.4K | 739.15K | 847.12K | 888.57K | 996.88K | 1.21M | 1.06M | 715.25K | 655.33K | 143.04K | 84.85K | -41.01K | -51.5K | 250.68K | -51.5K | 942 | 317.97K | 316.74K |
| EBIT | -114.28M | -104.05M | -81.42M | -40.94M | -15.18M | 0 | -3.44M | 0 | -5.28M | -6.73M | -6.31M | 0 | 0 | -4.59M | -4.07M | 0 | -2.96M | -4.01M | 0 | 0 | -9.7M | 0 | -4.1M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Interest Income | 7.57M | 7.74M | 10.56M | 850K | 1.12M | 0 | 59K | 30K | 108K | 29K | 118K | 217K | 281K | 11.23K | 657 | -60.94K | -213.22K | -24.96K | 35.74K | -274K | 0 | -1.02M | -165.1K | -2.1K | -41.01K | -51.5K | 0 | 0 | 12.44K | 0 | -163.27K |
| Interest Income | 7.93M | 8.11M | 10.52M | 934K | 1.12M | 119K | 59K | 30K | 108K | 29K | 118K | 218K | 283K | 12.11K | 664 | 747 | 3.38K | 11.43K | 111.05K | 0 | 0 | 0 | 2.39K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 353K | 376K | -48K | 84K | 0 | 119K | 0 | 0 | 0 | 0 | 0 | 1K | 2K | 883 | 7 | 61.68K | 216.61K | 36.39K | 75.31K | 274K | 0 | 1.02M | 167.49K | 2.1K | 41.01K | 51.5K | 0 | 0 | -12.44K | 0 | 163.27K |
| Other Income/Expense | 7.57M | 9.14M | -91.83M | 835K | 512K | 119K | 50K | 30K | 134K | 29K | 27K | 154K | 374.61K | -1.38M | 210K | 170K | 334K | 0 | 274K | -274K | 0 | -385.51K | -285.99K | -2.1K | -41.01K | -51.5K | 0 | 0 | 12.44K | 43.4K | 895.74K |
| Pretax Income | -112.44M | -104.43M | -81.38M | -40.11M | -14.67M | -7.27M | -3.39M | -3.45M | -5.14M | -6.7M | -6.16M | -4.71M | -3.68M | -5.96M | -3.86M | -3.43M | -2.84M | 0 | -6.2M | -9.08M | 0 | -8.22M | -4.27M | -60.03K | -59.08K | -59.08K | 0 | 0 | -3.09K | -423.98K | -2.15M |
| Pretax Margin % | -19554.78% | - | - | -2796.79% | -206.5% | -67.36% | -33.69% | -35.6% | -70.33% | -113.12% | -129.43% | -98.77% | -79.91% | -141.24% | -85.22% | -67.6% | -54.25% | - | -114.37% | -126.79% | - | -412.08% | -2116.28% | - | - | - | - | - | - | -5.4% | -26.03% |
| Income Tax | -793K | -793K | -2.1M | -2.65M | 0 | -119K | -199K | -177K | -294K | -29K | -145K | -371.19K | -655.14K | 1.37M | -210.66K | -109.06K | -120.78K | 24.96K | -309.74K | -245.21K | -94.67K | 1.02M | 0 | -84.85K | 41.01K | 51.5K | -250.68K | 51.5K | -942 | 2.1K | 2K |
| Effective Tax Rate % | 0.71% | 0.76% | 2.58% | 6.61% | 0% | 1.64% | 5.88% | 5.14% | 5.72% | 0.43% | 2.35% | 7.88% | 17.8% | -23.01% | 5.46% | 3.18% | 4.25% | - | 5% | 2.7% | - | -12.45% | 0% | 141.36% | -69.4% | -87.16% | - | - | 30.49% | -0.5% | -0.09% |
| Net Income | -111.13M | -103.12M | -79.28M | -46.51M | -14.67M | -7.15M | -3.19M | -3.27M | -4.85M | -6.7M | -6.16M | -4.71M | -3.68M | -5.96M | -3.86M | -3.49M | -2.84M | -4.03M | -6.16M | -8.56M | -9.61M | -8.22M | -4.27M | -60.03K | -59.08K | 235.11K | -65.65K | 1.82M | -139.55K | -426.08K | -2.15M |
| Net Margin % | -19327.48% | - | - | -3243.24% | -206.5% | -66.26% | -31.71% | -33.77% | -66.31% | -113.12% | -129.43% | -98.77% | -79.91% | -141.24% | -85.22% | -68.8% | -54.25% | -76.31% | -113.71% | -119.54% | -167.39% | -412.08% | -2116.28% | - | - | - | - | - | - | -5.43% | -26.06% |
| Net Income Growth % | -30.48% | -30.07% | -70.46% | -217.03% | -105.09% | -124.37% | 2.48% | 32.6% | 27.61% | -8.73% | -30.81% | -27.97% | 38.23% | -54.52% | -10.54% | -22.75% | 29.54% | 34.52% | 28.01% | 10.91% | -16.88% | -92.5% | -7012.11% | -1.6% | -125.13% | 458.13% | -103.6% | 1407.46% | 67.25% | 80.2% | -129.14% |
| Net Income (Continuing) | -111.65M | -103.64M | -80.43M | -37.45M | -14.67M | -7.15M | -3.19M | -3.27M | -4.85M | - | - | - | - | - | - | - | - | - | - | - | - | - | -4.27M | - | - | - | - | - | - | -426.08K | -2.15M |
| Discontinued Operations | 514K | 514K | -949K | -9.05M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.07 | -1.40 | -1.23 | -0.85 | -0.27 | -0.13 | -0.06 | -0.05 | -0.07 | -0.12 | -0.11 | -0.09 | -0.07 | -0.14 | -0.11 | -0.12 | -0.11 | -0.18 | -0.27 | -0.37 | -0.54 | -0.68 | -0.76 | -0.07 | -0.18 | 0.60 | -0.20 | 5.41 | -0.42 | -1.29 | -6.63 |
| EPS Growth % | -16.53% | -13.82% | -44.71% | -214.81% | -107.69% | -123.75% | -20.04% | 33.06% | 39.75% | -9.09% | -28.5% | -27.57% | 52.07% | -27.27% | 8.33% | -9.09% | 38.89% | 33.33% | 27.03% | 31.48% | 20.59% | 10.53% | -917.4% | 58.5% | -130% | 400% | -103.7% | 1388.1% | 67.44% | 80.54% | -102.75% |
| EPS (Basic) | - | -1.40 | -1.23 | -0.85 | -0.27 | -0.13 | -0.06 | -0.05 | -0.07 | -0.12 | -0.11 | -0.09 | -0.07 | -0.14 | -0.11 | -0.12 | -0.11 | -0.18 | -0.27 | -0.37 | -0.54 | -0.68 | -0.76 | -0.07 | -0.18 | 0.60 | -0.20 | 5.41 | -0.42 | -1.29 | -6.63 |
| Diluted Shares Outstanding | 103.6M | 73.81M | 64.42M | 54.91M | 54.91M | 54.91M | 54.91M | 67.6M | 67.04M | 55.16M | 55.02M | 55.02M | 54.88M | 42.68M | 34.42M | 28.62M | 25.13M | 22.96M | 22.94M | 23.03M | 17.83M | 12.05M | 5.62M | 804.04K | 329.23K | 329.23K | 329.23K | 329.23K | 329.23K | 329.23K | 324.73K |
| Basic Shares Outstanding | 103.6M | 73.81M | 64.42M | 54.91M | 54.91M | 54.91M | 54.91M | 67.6M | 67.04M | 55.16M | 55.02M | 55.01M | 54.88M | 42.68M | 34.42M | 28.62M | 25.13M | 22.96M | 22.94M | 23.03M | 17.83M | 12.05M | 5.62M | 804.04K | 329.23K | 329.23K | 329.23K | 329.23K | 329.23K | 329.23K | 324.73K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Clinical Trial Funding Gap
As indicated by the company's recent financial disclosures, quarterly revenue has fluctuated significantly, reaching a nominal $76.0K in 2026Q1, which underscores the lack of a consistent commercial engine as the firm pivots away from legacy medical device sales toward an unproven radiopharmaceutical development platform.
The intermittent nature of revenue generation suggests that the company has yet to establish a repeatable commercial model for its isotope-based products. Investors should monitor whether future revenue will be derived from sustainable clinical adoption or if it will remain tied to the legacy brachytherapy business, which appears to be in a state of structural decline.
Based on reported income statements, R&D expenditures have surged to $20.2M in 2026Q1, reflecting a strategic commitment to the Lead-212 platform that currently dwarfs the company's ability to generate meaningful gross profit or offset the high fixed costs associated with specialized nuclear manufacturing and regulatory compliance.
The aggressive scaling of R&D spending relative to negligible revenue indicates a high-risk transition phase where the company is prioritizing long-term clinical milestones over near-term expense discipline. This cost structure suggests that the firm is effectively operating as a pre-revenue biotech entity, necessitating constant capital infusions to sustain its current research trajectory.
According to the latest quarterly data, the company reported a gross margin of -13.8% in 2026Q1, a figure that highlights the inherent difficulty in managing the high-cost, decay-sensitive isotope supply chain while failing to achieve the necessary volume to cover basic production and logistics overheads.
The persistent inability to achieve positive gross margins suggests that the current production model is not yet economically viable. This margin profile warrants further investigation into whether the company can achieve scale-driven efficiencies or if the underlying cost of isotope procurement will continue to act as a structural drag on profitability.
As reported in financial filings, the company consistently utilizes stock-based compensation, with $2.3M recorded in 2025Q4, which serves to further dilute existing shareholders while the firm continues to post significant net losses, currently totaling $26.2M for the most recent quarter ending in 2026Q1.
The reliance on equity-based incentives in the absence of positive net income suggests that management is prioritizing talent retention in a competitive biotech landscape at the expense of shareholder dilution. Investors should monitor the impact of these non-cash charges on the overall capital structure as the company's cash runway continues to tighten.
Quick answers to the most common questions about buying CATX stock.
For fiscal year 2025, Perspective Therapeutics, Inc. (CATX) reported total revenue of $0.0M. This represents a 100.0% decline compared to $8.3M in 1996.
Perspective Therapeutics, Inc. (CATX) reported a net loss of $103.1M for the fiscal year ending 2025.